Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) on Saturday announced positive results from a long-term follow-up in patients that have been treated with bexicaserin (LP352) for up to two years.

Bexicaserin is an investigational compound in development for the treatment treatment of seizures related to Developmental and Epileptic Encephalopathies (DEEs).

DEEs are a group of severe, rare epilepsies that begin in childhood and require lifelong care.

The data, presented at the 2025 American Epilepsy Society Congress in Atlanta, USA (5-9 December), indicate that patients who achieved an early reduction in seizure frequency following bexicaserin treatment initiation, continue to maintain this reduction long-term.

Johan Luthman, EVP and head of Research and Development at Lundbeck, said: "The constant management of DEEs place a heavy emotional and financial burden on families, underscoring the urgent need for better seizure control. We are increasingly hopeful that bexicaserin can address this need. The data so far show durable seizure reductions, an encouraging safety profile and minimal risk of drug-drug interactions, reinforcing bexicaserin's potential as a first-in-class therapy across a broad range of DEEs."